GO
Loading...

Medicine

More

  • The drug was developed by Auxilium Pharmaceuticals Inc and Vivus Inc.. Vivus owns the worldwide development and commercial rights to Stendra for use in sexual dysfunction, with the exception of certain Asian countries in the Pacific Rim.

  • PARIS, Sept 18- French cancer immunotherapy specialist OSE Pharma has registered with market regulator AMF for an initial public offering aimed at financing late-stage trials of its Texopi drug for the most common form of lung cancer, the company said on Thursday.

  • Sept 18- An erectile dysfunction drug that reduces by half the time patients need to take the pill before sexual activity has been approved by the U.S. Food and Drug Administration.

  • Sept 17- Testosterone replacement therapies should be reserved for men with specific medical conditions that impair function of the testicles, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday. The FDA is not obliged to follow the advice of its advisory panels but typically does so.

  • Experts want restrictions on testosterone drug use Wednesday, 17 Sep 2014 | 3:59 PM ET

    The labeling change would drastically limit the drugs' FDA- approved indication to men who have abnormally low hormone levels due to disease or injury, instead of aging. For years companies like AbbVie and Eli Lilly have linked the condition to a variety of ailments in common in aging men, including sexual dysfunction and low mood.

  • Drugstores, retailers dive deeper into vaccines Wednesday, 17 Sep 2014 | 12:55 PM ET

    Walgreen provided enough flu shots last season to protect a population roughly twice the size of Los Angeles. And Wal-Mart, the world's largest retailer, offers flu shots at more than 4,200 of its U.S. stores that have pharmacies. Robert Wergin, a family physician in Milford, Nebraska, and president-elect of the American Academy of Family Physicians.

  • UPDATE 1-Gilead's experimental drug fails mid-stage study Wednesday, 17 Sep 2014 | 6:47 AM ET

    Sept 17- Gilead Sciences Inc said its experimental drug did not significantly improve how long patients with a type of pancreatic cancer lived without the disease worsening. Separately, the biotechnology company also licensed Sovaldi to seven India- based drugmakers that will sell far cheaper versions of the drug in 91 developing nations.

  • Pharma in focus: Ebola & Enterovirus D68     Tuesday, 16 Sep 2014 | 1:31 PM ET

    CNBC's Meg Tirrell runs down today's top health care headlines, including a major move by President Obama to fight the Ebola virus and the latest on Enterovirus D68.

  • Prescription painkiller deaths up, but not as fast Tuesday, 16 Sep 2014 | 12:01 AM ET

    NEW YORK— Overdose deaths from powerful painkillers are still rising in the U.S., but not like they used to— probably because of new restrictions on methadone, according to government scientists. In 2011, there were more than 41,000 drug overdose deaths nationwide, up from more than 38,000 the previous year.

  • Sept 15- Merck& Co said it will seek U.S. approval next year for its long-delayed experimental osteoporosis drug, odanacatib, after it proved effective in a late-stage trial but was associated with rare thigh-bone fractures seen with standard treatments.

  • Sept 15- Epirus Biopharmaceuticals Inc said India's drug regulator has approved its copy of a top-selling arthritis treatment, paving the way for its launch in the country early next year.

  • Sept 15- Avanir Pharmaceuticals Inc said its drug was more effective in reducing agitation associated with Alzheimer's, compared with a placebo, sending the company's shares up 55 percent to an over eight-year high.

  • *Gilead plans to sell Sovaldi in India for $300 a month. NEW DELHI/ MUMBAI, Sept 15- U.S. drugmaker Gilead Sciences Inc has licensed its hepatitis C drug Sovaldi to seven India- based drugmakers that will sell far cheaper versions of the $1,000- a-pill medicine in 91 developing nations.

  • Sept 15- Avanir Pharmaceuticals Inc said its drug was more effective in reducing agitation associated with Alzheimer's, compared with a placebo. The results from the mid-stage study pushed the company's shares up 28 percent before the bell.

  • *Acceptance for filing with priority review of supplemental new drug application for Vyvanse capsules for adults with binge eating disorder. *FDA is expected to provide a decision in February 2015, based on anticipated prescription drug user fee act action date. *Vyvanse should only be used to treat ADHD.

  • *Gilead plans to sell Sovaldi in India for $300 per month. NEW DELHI/ MUMBAI, Sept 15- U.S. drugmaker Gilead Sciences Inc has agreed to license its hepatitis C drug Sovaldi to seven India- based drugmakers to sell cheaper versions of the $1,000- a-pill medicine in 91 developing nations including India.

  • Gilead to license generic version of Sovaldi Monday, 15 Sep 2014 | 7:40 AM ET

    Gilead Sciences has reached a deal with several generic drugmakers to produce a cheaper version of its popular, $1,000- per-pill hepatitis C drug Sovaldi for use in developing countries.

  • Kids' poisonings linked to anti-addiction medicine Monday, 15 Sep 2014 | 12:01 AM ET

    CHICAGO— An anti-addiction drug used to fight the nation's heroin and painkiller abuse epidemics poses a threat to young children who accidentally swallow relatives' prescriptions, a federal study says.

  • LOS ANGELES, Sept 12- The next generation version of Gilead Sciences Inc's $84,000 hepatitis C drug, already under fire for its record-breaking costs, is going to be even more expensive.

  • The candidate Ebola vaccine is being co-developed by the United States National Institutes of Health and the British drugmaker GlaxoSmithKline. The trial will be led by Professor Adrian Hill of the Jenner Institute at Oxford University, which said on Friday the first shot is scheduled to be given to a human volunteer next week.